Compare PDS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | VRDN |
|---|---|---|
| Founded | 1951 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1998 | 2014 |
| Metric | PDS | VRDN |
|---|---|---|
| Price | $92.57 | $15.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $122.33 | $35.46 |
| AVG Volume (30 Days) | 81.6K | ★ 2.4M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $5.66 | $13.73 |
| Revenue Next Year | $2.31 | $279.00 |
| P/E Ratio | $884.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $48.00 | $13.18 |
| 52 Week High | $103.80 | $34.29 |
| Indicator | PDS | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 42.93 |
| Support Level | $88.08 | $15.65 |
| Resistance Level | $102.75 | $18.05 |
| Average True Range (ATR) | 3.76 | 0.86 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 31.32 | 6.56 |
Precision Drilling Corp is a provider of contract drilling, completion, and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. The company operates through two industry segments: Contract Drilling Services, which generates maximum revenue and includes drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale, and repair of drilling equipment; and Completion and Production Services, which includes service rigs, oilfield equipment rental, and camp services. The company generates the majority of its revenue from the United States.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.